The Committee for Veterinary Medicinal Products (CVMP) has adopted a positive opinion for the marketing authorization of Nobivac NXT HCPChFeLV, aimed at the active immunization of cats against multiple infectious diseases. This decision, made during the CVMP meeting held from April 14 to 16, 2026, underscores the committee’s ongoing commitment to enhancing animal health through innovative veterinary solutions.
As the veterinary market continues to evolve, the introduction of new vaccines like Nobivac NXT HCPChFeLV is crucial for addressing the growing concerns related to infectious diseases in pets. The positive opinion from CVMP not only reflects the rigorous assessment of the product’s safety and efficacy but also indicates the potential for increased competition in the veterinary pharmaceutical sector, which could lead to improved health outcomes for animals and expanded market opportunities for manufacturers.
Open the full market picture for your next decision →
